FDA Approves Verquvo (vericiguat) for Heart Failure with Reduced Ejection Fraction
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Verquvo, a soluble guanylate cyclase (sGC) stimulator, to reduce...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Canada Health | Cardiology | Drugs & Pharmacology | Food and Drug Administration (FDA) | Heart | Heart Failure | Merck | USA Health